Biotech Firm Arcturus Therapeutics Faces Mounting Pressure Ahead of Earnings

Shares of Arcturus Therapeutics are experiencing a severe downturn, weighed down by a combination of disappointing quarterly projections and newly disclosed legal challenges. The stock declined an additional 4.05% yesterday, closing at $8.29 and marking its fourth consecutive day of losses.

Legal Woes Compound Investor Concerns

The company’s troubles intensified with the revelation that two law firms have initiated investigations into Arcturus. The probes focus on potential securities law violations, which were triggered by an October 22nd press release concerning interim Phase 2 trial data for ARCT-032. This inhaled mRNA therapy for cystic fibrosis failed to demonstrate significant improvement in the lung function measure FEV1, causing the stock to plummet more than 50% upon the announcement. These legal developments have further eroded investor confidence in the biotech firm.

Third Quarter Forecasts Paint Bleak Picture

Market expectations are decidedly grim as Arcturus prepares to release its third-quarter 2025 results this Monday. Financial analysts are forecasting a loss of $1.25 per share, a substantial increase from the $0.26 per share loss recorded during the same period last year. Revenue projections are equally concerning, with estimates pointing to a dramatic 72.7% decline to just $11.39 million. This pessimistic outlook has prompted a significant sell-off among shareholders.

Should investors sell immediately? Or is it worth buying Arcturus Therapeutics?

Pipeline Assets Offer Glimmers of Hope

Despite the current challenges, Arcturus’s development pipeline contains several potentially promising programs. The company’s ARCT-810 program for OTC deficiency has reported positive interim Phase 2 data, with regulatory discussions about Phase 3 trial design scheduled for early 2026. Additionally, the H5N1 vaccine candidate ARCT-2304 received Fast Track designation from the FDA in April 2025, with Phase 1 results anticipated in the fourth quarter of 2025.

The technical chart pattern reveals a pronounced downward trajectory, with the stock having shed 30.92% of its value in just ten trading sessions. Whether the company can stage a recovery now hinges heavily on Monday’s earnings release and management’s response to these mounting pressures.